A groundbreaking study reveals a potential game-changer for newborn survival in Tanzania and beyond. The power of portable heart monitoring is about to revolutionize healthcare in low-resource settings. But here's where it gets controversial: is this technology the key to preventing newborn deaths, or just a luxury we can't afford?**
In a world where 99% of global newborn deaths occur in low- and middle-income countries (LMICs), access to adequate fetal monitoring is a luxury many pregnant women can't afford. Tanzania, with its high neonatal death rate, is a prime example. But a new wireless fetal heart rate monitoring technology is offering hope.
Researchers from Hiroshima University and Muhimbili University of Health and Allied Sciences evaluated a mobile cardiotocography device (iCTG) in four primary health facilities in Tanzania's Pwani region. The results, published in BMC Public Health, are nothing short of remarkable.
The iCTG device increased the detection of abnormal fetal heart rates by a staggering 8-10 times, and reduced the risk of stillbirths and neonatal deaths by more than half. Professor Yoko Shimpuku, corresponding author of the study, emphasizes, "iCTG is not a luxury; it's a lifesaving tool."
A wireless lifeline, indeed. The main causes of stillbirths and neonatal deaths in Tanzania are prematurity and hypoxia. Current fetal monitoring technology in LMICs is often immobile and expensive to maintain, or limited to basic tools like fetoscopes, which can miss critical signs of fetal distress. The iCTG, however, is smart, wireless, and user-friendly. It notifies healthcare providers of abnormalities, allowing for timely decisions and immediate treatment, such as intrauterine resuscitation or oxygen administration.
Between October 2023 and September 2024, the researchers enrolled 763 women at 32 weeks gestation or later. The results speak for themselves: perinatal mortality dropped significantly to 2.6% from 6.6% in the iCTG group. Fetal heart rate abnormalities were detected 8-10 times more frequently, and the proportion of newborns with low Apgar scores decreased significantly.
While the use of iCTG led to higher rates of caesarean sections (27.6% vs 10.3%), the researchers highlight the need for clear clinical guidelines to prevent unnecessary procedures. Surgical delivery can be life-saving when medically necessary, but it's a delicate balance.
Expanding access to this technology is crucial. Attendance at antenatal clinics (ANCs) can be low in LMICs due to various barriers. Previous research suggests that women with iCTG access are more likely to attend ANCs, but this study found the opposite. The team believes this is due to the late introduction of the intervention. They suggest using iCTG earlier in pregnancy to engage women and combine it with health education to increase ANC visits.
The researchers emphasize the need to integrate heart rate monitoring technology with other aspects of high-quality care. They plan to expand iCTG use to larger, more diverse settings while evaluating cost-effectiveness and long-term outcomes. Professor Shimpuku concludes, "Our aim is to ensure every pregnant woman, regardless of her location, has access to accurate fetal monitoring and safer childbirth."
This study, funded by the Japan Agency for Medical Research and Development, is a testament to the power of innovation and collaboration. The iCTG device, developed by Melody International Ltd., offers a glimmer of hope for a brighter future for newborns in Tanzania and potentially worldwide.
